Valiant Organics Ltd
Incorporated in 1984, Valiant Organics
Ltd manufactures and deals in specialty chemicals and pharma intermediates[1]
- Market Cap ₹ 685 Cr.
- Current Price ₹ 244
- High / Low ₹ 508 / 195
- Stock P/E 37.7
- Book Value ₹ 264
- Dividend Yield 0.00 %
- ROCE 2.63 %
- ROE -0.51 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.95 times its book value
Cons
- The company has delivered a poor sales growth of 1.27% over past five years.
- Company has a low return on equity of 3.58% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Specialty Chemicals
Part of BSE Allcap BSE Commodities
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|
| 692 | 675 | 755 | 1,153 | 1,052 | 723 | 719 | 725 | |
| 511 | 494 | 549 | 948 | 888 | 686 | 666 | 645 | |
| Operating Profit | 181 | 181 | 205 | 205 | 164 | 37 | 53 | 79 |
| OPM % | 26% | 27% | 27% | 18% | 16% | 5% | 7% | 11% |
| 8 | 6 | 6 | 7 | 13 | 6 | 8 | 10 | |
| Interest | 4 | 3 | 5 | 6 | 11 | 16 | 24 | 19 |
| Depreciation | 14 | 16 | 21 | 30 | 29 | 35 | 36 | 39 |
| Profit before tax | 171 | 168 | 185 | 176 | 137 | -9 | 2 | 32 |
| Tax % | 29% | 25% | 29% | 27% | 25% | -3% | 260% | |
| 121 | 126 | 131 | 128 | 103 | -8 | -3 | 22 | |
| EPS in Rs | 103.65 | 51.00 | 42.19 | 41.72 | 32.45 | -3.04 | -1.34 | 7.75 |
| Dividend Payout % | 6% | 11% | 12% | 8% | 3% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 1% |
| 3 Years: | -15% |
| TTM: | 5% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 196% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -26% |
| 3 Years: | -17% |
| 1 Year: | -1% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 10% |
| 3 Years: | 4% |
| Last Year: | -1% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6 | 12 | 27 | 27 | 27 | 28 | 28 | 28 |
| Reserves | 254 | 374 | 475 | 586 | 662 | 702 | 697 | 712 |
| 77 | 140 | 209 | 364 | 274 | 257 | 249 | 236 | |
| 112 | 143 | 165 | 216 | 276 | 262 | 209 | 187 | |
| Total Liabilities | 448 | 669 | 876 | 1,192 | 1,239 | 1,248 | 1,183 | 1,163 |
| 150 | 276 | 510 | 543 | 670 | 643 | 657 | 707 | |
| CWIP | 66 | 129 | 46 | 112 | 71 | 86 | 66 | 9 |
| Investments | 12 | 23 | 6 | 8 | 41 | 99 | 94 | 152 |
| 221 | 241 | 314 | 529 | 457 | 420 | 367 | 295 | |
| Total Assets | 448 | 669 | 876 | 1,192 | 1,239 | 1,248 | 1,183 | 1,163 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| 76 | 161 | 113 | -31 | 238 | 84 | 56 | |
| -86 | -184 | -156 | -124 | -143 | -65 | -21 | |
| 1 | 27 | 49 | 167 | -112 | -23 | -32 | |
| Net Cash Flow | -9 | 5 | 5 | 12 | -17 | -4 | 4 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 75 | 72 | 76 | 102 | 88 | 106 | 90 |
| Inventory Days | 44 | 42 | 63 | 54 | 68 | 88 | 71 |
| Days Payable | 69 | 82 | 93 | 63 | 89 | 159 | 119 |
| Cash Conversion Cycle | 50 | 32 | 45 | 93 | 67 | 34 | 42 |
| Working Capital Days | 46 | 20 | -1 | 21 | 11 | -3 | -10 |
| ROCE % | 39% | 30% | 21% | 14% | 1% | 3% |
Insights
In beta| Mar 2021 | Mar 2023 | Sep 2024 | Sep 2025 | |
|---|---|---|---|---|
| Total Production Capacity TPA |
|
|||
| Gross Current Assets (GCA) Days Days ・Standalone data |
||||
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Investor Presentation 25 Feb
- Announcement under Regulation 30 (LODR)-Newspaper Publication 14 Feb
-
Financial Results For The Quarter Ended December 31, 2025.
13 Feb - Approved Q3 and 9M results to Dec 31, 2025; 9M standalone profit Rs1,923.82L; Rs572.08L exceptional insurance gain.
-
Board Meeting Outcome for Outcome Of Board Meeting
13 Feb - Board approved Q3 and 9M FY26 results; standalone 9M net profit Rs1,923.82 lakh; Rs572.08 lakh insurance gain.
-
Board Meeting Intimation for Approval Of Unaudited Financial Statement For The Quarter Ended December 31, 2025
9 Feb - Board meeting Feb 13, 2026 to consider unaudited results for quarter ended Dec 31, 2025; trading window closed until Feb 15, 2026.
Annual reports
Concalls
-
Feb 2026TranscriptAI SummaryPPT
-
Nov 2025TranscriptAI SummaryPPT
-
Sep 2025TranscriptAI SummaryPPT
-
Aug 2025TranscriptAI SummaryPPT
-
Jul 2025TranscriptAI SummaryPPT
-
May 2025TranscriptAI SummaryPPT
-
Feb 2025TranscriptAI SummaryPPT
-
Dec 2024TranscriptAI SummaryPPT
-
Aug 2024TranscriptAI SummaryPPT
-
Jun 2024TranscriptAI SummaryPPT
-
May 2024TranscriptAI SummaryPPT
-
Feb 2024Transcript PPT REC
-
Nov 2023Transcript PPT
-
Sep 2023Transcript PPT
-
Aug 2023TranscriptAI SummaryPPT
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Feb 2023TranscriptAI SummaryPPT
-
Nov 2022Transcript PPT
-
Nov 2022TranscriptAI SummaryPPT
-
Sep 2022TranscriptAI SummaryPPT
-
Aug 2022Transcript PPT
-
Jul 2022TranscriptAI SummaryPPT
-
May 2022Transcript PPT
-
Mar 2022TranscriptAI SummaryPPT
-
Mar 2022TranscriptAI SummaryPPT
-
Feb 2022TranscriptAI SummaryPPT
-
Sep 2021TranscriptAI SummaryPPT
Business Overview:[1][2][3]
VOL is is promoted by Gogri, Chedda and Gala families. It manufactures specialty chemicals and is one of the largest manufacturers of chlorophenol derivatives, Benzene derivatives, PNA, PAP, Ortho Anisidine and Para Anisidine.
Product Portfolio[4]
1. Ammonolysis
Products include Para Nitro Aniline and Ortho Chloro Para Nitro Aniline, primarily serving the dyes and pigments industries.
2. Hydrogenation
The product range comprises Ortho Anisidine, Para Anisidine, IPPCA, Meta Chloro Aniline, Para Amino Phenol, and Ortho Amino Phenol, catering to dyes, pigments, pharmaceuticals, and agrochemicals sectors.
3. Chlorination
Key products are Para ChloroPhenol (PCP), Ortho ChloroPhenol (OCP), 2,4 Di ChloroPhenol (2,4 DCP), 2,6 Di ChloroPhenol (2,6 DCP), and 2,4,6 Tri ChloroPhenol (2,4,6 TCP), widely used in agrochemicals, cosmetics, veterinary, and pharmaceutical applications.